We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Analysis of Genotoxic Nitrosamines in Losartan

Analysis of Genotoxic Nitrosamines in Losartan content piece image

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) continue to closely monitor nitrosamine levels in pharmaceutical products since the initial discovery of N-nitrosodimethylamine (NDMA) in valsartan in 2018 prompted recalls of the drug. These recalls highlight the ongoing need for sensitive, selective methods for the analysis of multiple nitrosamines in pharmaceutical products prone to contamination by these potentially carcinogenic compounds.

Download this app note to discover a system that:

  • Demonstrates good chromatographic separation of nitrosamine compounds
  • Provides enhanced sensitivity
  • Is fully compliant with 21 CFR Part 11